JP4555476B2 - 縮合アゼピノン型サイクリン依存性キナーゼ阻害物質 - Google Patents

縮合アゼピノン型サイクリン依存性キナーゼ阻害物質 Download PDF

Info

Publication number
JP4555476B2
JP4555476B2 JP2000554735A JP2000554735A JP4555476B2 JP 4555476 B2 JP4555476 B2 JP 4555476B2 JP 2000554735 A JP2000554735 A JP 2000554735A JP 2000554735 A JP2000554735 A JP 2000554735A JP 4555476 B2 JP4555476 B2 JP 4555476B2
Authority
JP
Japan
Prior art keywords
dihydro
indolo
benzazepine
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000554735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002518395A5 (https=
JP2002518395A (ja
Inventor
コンラッド クニク
ローレン メイジャー
ダニエル ダブリュー． ザハレビッツ
リック ギュッシオ
ラビ ケイ． ジャルーリ
エドワード エイ． ソースビル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2002518395A publication Critical patent/JP2002518395A/ja
Publication of JP2002518395A5 publication Critical patent/JP2002518395A5/ja
Application granted granted Critical
Publication of JP4555476B2 publication Critical patent/JP4555476B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2000554735A 1998-06-16 1999-06-16 縮合アゼピノン型サイクリン依存性キナーゼ阻害物質 Expired - Fee Related JP4555476B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8961998P 1998-06-16 1998-06-16
US60/089,619 1998-06-16
PCT/US1999/013579 WO1999065910A1 (en) 1998-06-16 1999-06-16 Fused azepinone cyclin dependent kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2002518395A JP2002518395A (ja) 2002-06-25
JP2002518395A5 JP2002518395A5 (https=) 2006-04-20
JP4555476B2 true JP4555476B2 (ja) 2010-09-29

Family

ID=22218651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000554735A Expired - Fee Related JP4555476B2 (ja) 1998-06-16 1999-06-16 縮合アゼピノン型サイクリン依存性キナーゼ阻害物質

Country Status (8)

Country Link
US (1) US6610684B2 (https=)
EP (1) EP1086105B1 (https=)
JP (1) JP4555476B2 (https=)
AT (1) ATE318818T1 (https=)
AU (1) AU778735B2 (https=)
CA (1) CA2335115C (https=)
DE (1) DE69930120T2 (https=)
WO (1) WO1999065910A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804959B1 (fr) * 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
JP4527404B2 (ja) 2002-04-04 2010-08-18 エンゾン，インコーポレーテッド インドールのポリマー性アシル誘導体
DE10260618B4 (de) * 2002-12-23 2005-06-09 Faustus Forschungs Cie. Translational Cancer Research Gmbh Tumorhemmende annellierte Azepinonderivate
PL1748691T3 (pl) * 2004-05-12 2011-04-29 Bayer Cropscience Ag Sposób regulacji wzrostu roślin
WO2006089874A1 (en) * 2005-02-22 2006-08-31 Gpc Biotech Ag Benzo[2,3]azepino[4,5-b]indol-6-ones
EP1757607A1 (en) 2005-08-24 2007-02-28 Molisa GmbH N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
WO2009010298A2 (en) * 2007-07-18 2009-01-22 Technische Universität Carolo-Wilhelmina Zu Braunschweig Paullone derivatives and its use
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
JP2012504646A (ja) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
CN102231983A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
EP2414358A1 (en) * 2009-03-31 2012-02-08 ArQule, Inc. Substituted tetrahydropyrazolo-pyrido-azepin compounds
EP3406260B1 (en) 2009-05-13 2020-09-23 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US8637501B2 (en) * 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
KR20120060201A (ko) 2009-07-08 2012-06-11 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 기능적으로 분화된 체세포의 연장된 자기재생을 유도하는 방법
WO2011112635A1 (en) 2010-03-08 2011-09-15 Sloan-Kettering Institute For Cancer Research Cdc7 kinase inhibitors and uses thereof
EP2640394A4 (en) 2010-11-17 2015-02-25 Univ North Carolina PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
HK1222766A1 (zh) 2013-03-15 2017-07-14 G1治疗公司 高效的抗赘生剂和抗增生剂
DK2968290T3 (da) 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
WO2015161285A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EA201891170A1 (ru) 2015-11-18 2018-11-30 Джензим Корпорейшн Биомаркер поликистозной болезни почек и варианты его применения
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022104206A1 (en) * 2020-11-13 2022-05-19 Neuron23, Inc. Kinase modulators and methods of use thereof
EP4277897A1 (en) * 2021-01-12 2023-11-22 Chengdu Anticancer Bioscience, Ltd. Fused azepine compounds and their use in the treatment of cancer
US12258345B1 (en) 2023-12-12 2025-03-25 King Faisal University Pyrrolo[3,2-c]isoquinoline-2,3-dione compounds as CK2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642779A (en) * 1969-10-22 1972-02-15 Robins Co Inc A H Indolo(1 2-d)(1 4)benzodiazepin-6-ones
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
ATE239020T1 (de) * 1996-10-09 2003-05-15 Schering Corp Tricyclische verbindungen als ras-fpt inhibitoren

Also Published As

Publication number Publication date
EP1086105A1 (en) 2001-03-28
CA2335115C (en) 2009-01-27
CA2335115A1 (en) 1999-12-23
DE69930120D1 (de) 2006-04-27
US20020042412A1 (en) 2002-04-11
AU4571499A (en) 2000-01-05
EP1086105B1 (en) 2006-03-01
ATE318818T1 (de) 2006-03-15
US6610684B2 (en) 2003-08-26
WO1999065910A9 (en) 2000-03-16
JP2002518395A (ja) 2002-06-25
DE69930120T2 (de) 2006-11-02
WO1999065910A1 (en) 1999-12-23
AU778735B2 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
JP4555476B2 (ja) 縮合アゼピノン型サイクリン依存性キナーゼ阻害物質
JP5694172B2 (ja) カルバゾール化合物および当該化合物の治療用途
EP1177185B1 (en) 4, 5, 6, 7-tetrahydroindazole derivatives as antitumor agents
SK56195A3 (en) Pyrrolopyrimidine derivatives with pharmacologic effeciency
TW200829589A (en) Compound for inhibiting mitotic progression
KR20020038730A (ko) 이성질체 접합 피롤로카르바졸 및 이소인돌론
WO2024008129A1 (zh) 作为kat6抑制剂的化合物
TWI523856B (zh) BCR-ABL kinase inhibitor and its application
WO2023116696A1 (zh) 蛋氨酸腺苷转移酶2a的杂环抑制剂
CN111542522A (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
IE913598A1 (en) Heterocyclic compounds
CN120302969A (zh) 可用作iap抑制剂的化合物和组合物
US8008320B2 (en) 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
KR900006756B1 (ko) 벤조티에피노[5,4-c]피리다진 화합물 및 그의 약학적 용도
US4497814A (en) 2-(Pyridinyl)-1,2,4-triazolo[1,5-a]pyrimidines and derivatives useful in increasing cardiac contractility
JP2726999B2 (ja) イミダゾ［２，１−ｂ］ベンゾチアゾール誘導体及び該化合物を有効成分とする抗潰瘍剤
CN118772164A (zh) 蛋白精氨酸甲基转移酶抑制剂
CZ20022222A3 (cs) Nové substituované pyrazolo [4,3-e] diazepiny, farmaceutické kompozice obsahující tyto diazepiny, jejich použití jako léčiva a způsoby jejich přípravy
CN103906751A (zh) 作为晚期SV40因子（LSF）抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物
WO2000041689A1 (en) Telomerase inhibitors
KR20250011138A (ko) Ptpn2 저해제
WO2002079204A1 (en) 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivative
JP7143437B2 (ja) Ｆｍｓ様チロシンキナーゼ阻害剤
CN113527311A (zh) Fgfr4抑制剂、组合物及其在药物制备中的用途
AU780528B2 (en) Fused azepinone cyclin dependent kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20010531

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091019

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100506

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100601

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100623

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100716

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130723

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130723

Year of fee payment: 3

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees